Target intelligence / Profile preview

Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant (KRAS G12D)

Target
KRAS G12D
Molecular classification
GTPase, Oncoprotein
01

Overview

The KRAS G12D mutation is a common activating mutation in the KRAS gene, where glycine at codon 12 is replaced by aspartic acid. This mutation impairs GTP hydrolysis, locking KRAS in its active state and constitutively activating downstream signaling pathways like RAF-MEK-ERK and PI3K-AKT-mTOR, driving uncontrolled cell growth and survival. It is prevalent in cancers such as pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma. Recent structural studies have identified that selective inhibitors can target specific conformations unique to mutant forms like KRAS(G12D), such as the switch II pocket.

Other names
KRAS(G12D)KRAS p.Gly12AspKRAS G12D mutant
02

Mechanism of action

Inhibition of KRAS G12D mutant by targeting the switch II pocket.

03

Biological functions

Signal transductionCell proliferationCell survivalRegulation of cell growthActivating downstream signaling pathways (RAF-MEK-ERK, PI3K-AKT-mTOR)
04

Disease associations

CancerPancreatic ductal adenocarcinomaColorectal cancerNon-small cell lung cancer
05

Safety considerations

Potential for off-target effectsResistance developmentToxicity of inhibitors
06

Interacting drugs

MRTX1133
07

Biomarkers

KRAS G12D mutation status for targeted therapy selection

Beyond the preview

Go deeper on Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant (KRAS G12D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant (KRAS G12D).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call